Phunware COO Jeremy Krol Separates From Company

Phunware's COO Jeremy Krol left the company without cause, effective November 6, 2026. The company plans to negotiate a separation agreement with Krol, but no terms have been finalized. According to the company, Krol's departure is not due to any misconduct.

Original reporting
Published Nov 13, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 9:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Phunware COO Jeremy Krol Separates From Company — source image
Decision brief

The 30-second read

$PHUNBearishLow
01

Why it matters

The separation is a primary disclosure via an 8‑K, indicating a material change in senior management.

02

Market read

The news is a direct, first‑report filing that may affect Phunware's share price in the short term.

03

What to watch

The filing provides no details on a replacement; the market may be under‑estimating the possibility of a smooth transition.

Relevance 7/10Novelty 6/10Timing: effective today

Background

Phunware (NASDAQ:PHUN) is a mobile‑app and digital‑experience platform provider. Executive changes are material for investors monitoring leadership continuity.

Company-level read

Ticker impact

$PHUNBearishMedium confidence
Context

Phunware filed an 8‑K reporting COO Jeremy Krol's separation without cause, effective November 6, 2026.

Expected impact

likely downward pressure as investors assess the impact of the COO exit

Evidence & confidence

Executive departures often trigger short‑term sell‑side sentiment, especially for small‑cap firms with limited leadership depth.

Market effects

Minimal; the change is specific to Phunware and does not affect the broader mobile‑app or ad‑tech sector.

None; the news is company‑specific.

Low; limited impact beyond the stock itself.

Counterpoint

The COO's exit could be a catalyst for a strategic reset, potentially unlocking value if new leadership improves execution.

Key entities

  • Jeremy Krol

    Chief Operating Officer of Phunware, separated without cause.

Related articles

$MDCXMed

Small cap wrap: Phunware, Trust Stamp, Medicus Pharma, TNR

TNR Gold (TSX-V:TNR, OTC:TRRXF) agreed to a $122M acquisition by Altius Minerals at a 60% premium. Grey Matters Health (CSE:GREY, OTCQB:AGNPD) gained Medicare/Medicaid accreditation. Snail Inc (NASDAQ:SNAL) received a positive analyst note after Q3 revenue growth. Summit Therapeutics (NASDAQ:SMMT) shares fell 12.69% after FDA rejection. Citi initiated coverage of Amaroq Minerals (AIM:AMRQ, TSX-V:AMRQ) with a 'buy' rating. BioVie (NASDAQ:BIVI, NASDAQ:BIVIW) presented Long COVID trial findings.

$PHUNMedAI 8/10

Phunware Reports Third Quarter 2026 Financial Results

Phunware, Inc. (PHUN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Phunware Reports Third Quarter 2026 Financial Results Advances Phunware 2.0 Rollout, with Four Major Hospitality Groups in Discussions Gross Profit Increases 61.2%; Gross Margin Expands to 56.7% from 38.1% Ends Quarter with $86.7 Million in Cash and No Debt AUSTIN, Texas – Novemb

$PHUNMed

Phunware lifts third-quarter revenue 8% as gross margin expands

Phunware Inc (PHUN) reported Q3 revenue growth of 8.3% to $483,000, with gross margin expanding to 56.7% from 38.1%. The company holds $86.7M in cash with no debt. CEO Dmitry Kroshka highlighted a shift to a modular platform targeting the hospitality and healthcare markets. Phunware also reported a net loss of $7.1M, attributed to litigation and AI development costs.

$PHUNMed

Phunware Reports Second Quarter 2026 Financial Results

Phunware, Inc. (PHUN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Phunware Reports Second Quarter 2026 Financial Results Revenue Increased 76% Year-Over-Year, Gross Margin Expanded to 69% Maintained $92 Million Cash Position with No Debt to Support Continued Product Innovation and Growth Appointed Chief Executive Officer and Senior Vice Preside

$AVRMedAI 8/10

Anteris Reports Strong One-Year Results For DurAVR Heart Valve In High-Risk Aortic Stenosis Patients

Anteris Technologies (AVR) reported one-year data for its DurAVR heart valve, showing strong performance in high-risk aortic stenosis patients. Key metrics include 1% hospitalization for heart failure, 8.9 mmHg mean pressure gradient, and 96% of patients with mild or no symptoms post-treatment. The study involved 100 patients with complex conditions. Anteris stock closed at $4.99, up to $5.09 in after-hours trading.